



Patient ID SA00078436	Patient Name TESTINGRNA, REPORT	Birth Date 1999-11-11	Gender M	Age 16
Order Number SA00078436	Client Order Number SA00078436	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 30 Aug 2016 06:00		

JAK2 V617F Mutation Detection, B

JAK2 Result

MCR

see interpretation

are considered equivalent.

Signing Pathologist: Melissa Tricker-Klar

JAK2 V617F Mutation Detection, B

1 MCR

Peripheral blood, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 22% of total JAK2 DNA.

Note: Starting from 01/12/2016, the calculation and reporting value of JAK2V617F/total JAK2% is changed to more accurately reflect the true JAK2V617F allele burden. Higher values are generally expected and for levels below 80% (currently reported with new calculation), 1–5 fold increase from the prior calculation is expected. The testing method is not changed, however the limit of analytic sensitivity is changed to 0.06%. Please contact the Molecular Hematopathology Laboratory at 855–516–8404 if you have questions or concerns.

ADDITIONAL INFORMATION

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.06% (see Mayo Clinic Laboratories Interpretive Handbook for method details).

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50–60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value

Received: 30 Aug 2016 12:51

Reported: 30 Aug 2016 13:44

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292